Resverlogix Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Donald J. McCaffrey
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4820 Richard Road SW Calgary AB Canada T3E 6L1
- IPO Date
- Feb 13, 2009
- Website
- resverlogix.com
- Similar Companies
- Business
- Resverlogix Corp. Resverlogix Corp. (TSX: RVX), founded in 2001 and headquartered in Calgary, Alberta, Canada, operates as a late-stage clinical biotechnology company focused on developing epigenetic therapies to treat patients with chronic diseases, including cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, neurodegenerative disorders, and post-COVID-19 conditions. The company pioneers gene regulation through inhibition of bromodomain and extraterminal domain (BET) proteins; its lead product, apabetalone (RVX-208), represents the most advanced epigenetic drug outside oncology and serves as the world leader in this novel class of small-molecule selective BET inhibitors designed to restore biological functions altered by serious illnesses. Apabetalone targets high-risk cardiovascular patients, including those with low high-density lipoprotein cholesterol and recent acute coronary syndrome, and has completed the global Phase 3 BETonMACE clinical trial evaluating its efficacy in combination with standard statin therapies like Lipitor and Crestor; the company also advances pipeline candidates such as RVX-308, RVX-408, and TGF-beta Shield for coronary artery disease, APOA1-related cardiovascular indications, and neoplasms, while providing value-based health solutions to pharmaceutical, physician, and payer stakeholders. Resverlogix maintains operations primarily in Canada with an additional office in San Francisco, California, and targets global markets through strategic partnerships; it collaborates with EVERSANA for rapid commercialization of apabetalone in cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension across the United States and Canada, as well as with Medison Pharma Ltd. for broader distribution support. In recent developments, the company extended its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. by two years to May 13, 2026, eliminated conversion privileges, and increased the interest rate to 18% per annum effective May 14, 2024, enhancing financial stability amid ongoing clinical and commercialization efforts. These moves, announced in mid-2024, underscore Resverlogix's focus on securing funding for apabetalone's regulatory pathways and market entry while advancing epigenetic innovations for unmet needs in chronic disease management.
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Resverlogix Announces One-Year Extension of Debenture
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Resverlogix Corp. Announces Issuance of MCTO by ASC
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
Resverlogix Appoints Bradley Glass to Board of Directors
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
Resverlogix Announces Change to Its Board of Directors
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.